These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31393093)

  • 21. Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma.
    Saarinen-Pihkala UM; Hovi L; Koivusalo A; Jahnukainen K; Karikoski R; Sariola H; Wikström S
    Pediatr Blood Cancer; 2012 Dec; 59(7):1190-7. PubMed ID: 22492714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
    Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
    Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tandem high-dose chemotherapy with topotecan-thiotepa-carboplatin and melphalan-etoposide-carboplatin regimens for pediatric high-risk brain tumors.
    Choi JY; Kang HJ; Hong KT; Hong CR; Lee YJ; Park JD; Phi JH; Kim SK; Wang KC; Kim IH; Park SH; Choi YH; Cheon JE; Park KD; Shin HY
    Int J Clin Oncol; 2019 Dec; 24(12):1515-1525. PubMed ID: 31352632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
    Hawkins D; Barnett T; Bensinger W; Gooley T; Sanders J
    Med Pediatr Oncol; 2000 May; 34(5):328-37. PubMed ID: 10797354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
    Cabrero M; Martin A; Briones J; Gayoso J; Jarque I; López J; Grande C; Heras I; Arranz R; Bernal T; Perez-Lopez E; López-Godino O; Conde E; Caballero D
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):53-59. PubMed ID: 27771496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.
    Pérez-Martínez A; Lassaletta A; González-Vicent M; Sevilla J; Díaz MA; Madero L
    J Neurooncol; 2005 Jan; 71(1):33-8. PubMed ID: 15719272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation.
    Demirer T; Uysal VA; Ayli M; Genc Y; Ilhan O; Koc H; Dagli M; Arat M; Gunel N; Fen T; Dincer S; Ustael N; Yildiz M; Ustun T; Seyrek E; Ozet G; Muftuoglu O; Akan H
    Bone Marrow Transplant; 2003 May; 31(9):755-61. PubMed ID: 12732881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
    Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
    Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
    Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
    Ozkaynak MF; Sahdev I; Gross TG; Levine JE; Cheerva AC; Richards MK; Rozans MK; Shaw PJ; Kadota RP
    J Pediatr Hematol Oncol; 2008 Mar; 30(3):204-9. PubMed ID: 18376282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: a Pediatric Blood and MarrowTransplant Consortium study.
    Gilman AL; Jacobsen C; Bunin N; Levine J; Goldman F; Bendel A; Joyce M; Anderson P; Rozans M; Wall DA; Macdonald TJ; Simon S; Kadota RP
    Pediatr Blood Cancer; 2011 Sep; 57(3):506-13. PubMed ID: 21744474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloablative Carboplatin and Thiotepa With Autologous Stem Cell Rescue for Nonmedulloblastoma High-risk CNS Tumors in Young Children.
    Fries C; Girvin AR; Korones DN; Weintraub L; Fitzpatrick L; Andolina JR
    J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1223-e1227. PubMed ID: 34001790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
    Lee JL; Gooley T; Bensinger W; Schiffman K; McDonald GB
    Biol Blood Marrow Transplant; 1999; 5(5):306-15. PubMed ID: 10534061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.
    Fenk R; Liese V; Neubauer F; Bruns I; Kondakci M; Balleisen S; Saure C; Schröder T; Haas R; Kobbe G
    Leuk Lymphoma; 2011 Aug; 52(8):1455-62. PubMed ID: 21657961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
    Sugimoto M; Ito S; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Ashizawa M; Yamamoto C; Fujiwara S; Okazuka K; Hatano K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kako S; Kanda Y
    Ann Hematol; 2016 Sep; 95(9):1513-9. PubMed ID: 27365141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa.
    McCoy AG; Smith EP; Atkinson ME; Baranski B; Kahl BS; Juckett M; Mitchell T; Gangnon R; Longo WL
    Bone Marrow Transplant; 2004 Jan; 33(1):19-24. PubMed ID: 14704653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
    Meisenberg BR; Miller WE; McMillan R
    Bone Marrow Transplant; 1996 Dec; 18(6):1087-93. PubMed ID: 8971377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.